| Description |
1 online resource (566 pages) |
| Contents |
Cover; Title Page; Copyright; Contents; List of Contributors; Preface; Historical Perspective: What Makes Antibody-Drug Conjugates Revolutionary?; Introduction; Early Work in Monoclonal Antibody Development: Ehrlich's Magic Bullets; Use of Monoclonal Antibodies to Identify and Treat Cancer; Linking Monoclonal Antibodies with Cytotoxic Agents; Antibody-Drug Conjugates in the Clinic; Why ADCs Are Revolutionary?; References; Part I 1 What is an Antibody-Drug Conjugate; Chapter 1 Typical Antibody-Drug Conjugates; 1.1 Introduction; 1.1.1 A Simple Concept |
|
1.1.2 Turning Antibodies into Potent Anticancer Compounds1.1.3 What is a Typical ADC and How Does it Act?; 1.1.4 Simple Concept, but Not So Simple to Execute; 1.2 The Building Blocks of a Typical ADC; 1.2.1 The Antibody; 1.2.1.1 Antibody Isotype in ADCs; 1.2.1.2 Functional Activity of the Antibody Moiety in ADCs; 1.2.2 The Payload; 1.2.2.1 DNA-Targeting Payloads; 1.2.2.2 Payloads Targeting Tubulin; 1.2.3 Linker Chemistries; 1.3 Building an ADC Molecule; 1.3.1 Conjugation of Payloads to Antibodies at Lysine Residues; 1.3.2 Conjugation of Payloads to Antibodies at Cysteine Residues |
|
1.4 Attributes of a Typical ADC1.4.1 Structural Attributes of a Typical ADC; 1.4.2 Functional Characteristics of a Typical ADC; 1.4.2.1 In Vitro Properties; 1.4.2.2 In Vivo Efficacy; 1.4.2.3 Pharmacokinetics of ADCs; 1.5 Summary; Acknowledgment; References; Part II Engineering, Manufacturing, and Optimizing Antibody-Drug Conjugates; Chapter 2 Selecting Optimal Antibody-Drug Conjugate Targets Using Indication-Dependent or Indication-Independent Approaches; 2.1 Characteristics of an Optimal ADC Target; 2.2 Indication-Dependent ADC Target Selection |
|
2.3 Indication-Independent ADC Target Selection2.4 Concluding Remarks and Future Directions; Acknowledgments; References; Chapter 3 Antibody-Drug Conjugates: An Overview of the CMC and Characterization Process; 3.1 Introduction; 3.2 ADC Manufacturing Process; 3.2.1 Conjugation; 3.2.2 Conjugation -- Next-Generation Chemistry; 3.2.2.1 Conjugation -- Novel Payloads; 3.2.2.2 Conjugation -- Linker Design; 3.2.3 mAb Engineering; 3.2.4 Purification; 3.2.5 Formulation; 3.3 Characterization; 3.3.1 Quality and Stability Testing; 3.3.2 Biochemical and Microbiological Testing |
|
3.3.3 Extended Characterization3.4 Comparability; 3.5 Concluding Remarks; References; Chapter 4 Linker and Conjugation Technology; and Improvements; 4.1 Overview; 4.2 Noncleavable; 4.3 Cleavable Linkers and Self-Immolative Groups; 4.4 Differences in Therapeutic Window of Cleavable and Noncleavable Linkers; 4.5 Improving Therapeutic Window with Next-Generation Linker Technologies; 4.6 Site-Specific Conjugation, Homogeneous Drug Species, and Therapeutic Window; 4.7 Influence of Linkers on Pharmacokinetics and ADME; 4.8 PEG Linkers to Optimize Clearance, Solubility, and Potency |
| Summary |
Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. - Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies- Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging- Includes case studies of ADCs in oncology drug development- Features contributions from highly-regarded experts on the frontlines of ADC research and development |
| Notes |
4.9 Linkers to Optimize for Drug Resistance |
|
Print version record |
| Subject |
Antibody-toxin conjugates.
|
|
Monoclonal antibodies.
|
|
Antineoplastic agents.
|
|
Tumors -- Treatment
|
|
Antimitotic agents.
|
|
Immunoconjugates
|
|
Immunotoxins
|
|
Antibodies, Monoclonal
|
|
Antimitotic Agents
|
|
Antineoplastic Agents
|
|
MEDICAL -- Pharmacology.
|
|
Antimitotic agents
|
|
Antibody-toxin conjugates
|
|
Antineoplastic agents
|
|
Monoclonal antibodies
|
|
Tumors -- Treatment
|
| Form |
Electronic book
|
| Author |
Hurvitz, Sara A
|
| ISBN |
9781119060802 |
|
111906080X |
|
